RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
מצבים רפואיים
Systemic Sclerosis · Scleroderma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Yale University, New Haven, Connecticut, United States
Contact: Principal Investigator (Dr. Monique Hinchcliff, MD, MS)Mayo Clinic Florida, Jacksonville, Florida, United States
Contact: Principal Investigator (Dr. Andy Abril, MD)Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Principal Investigator (Dr. George Georges, MD)The University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Principal Investigator (Dr. Michael Macklin, MD)University of Kansas Medical Center, Kansas City, Kansas, United States
Contact: Principal Investigator (Dr. Paul Schmidt, MD)University of Michigan, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Monalisa Ghosh, MD)Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Ashima Makol, MD)Columbia University Irving Medical Center, New York, New York, United States
Contact: Principal Investigator (Elana Bernstein, MD)University of Rochester, Rochester, New York, United States
Contact: Principal Investigator (Benjamin Korman, M.D.)Duke University, Durham, North Carolina, United States
Contact: Principal Investigator (Ankoor Shah, MD)
מובילי המחקר
Medical Director
Study Director
Cabaletta Bio